Hidradenitis Suppurativa and Psoriasis: Can Anti-IL-17/23 Drugs Help?

Hidradenitis suppurativa (HS) and psoriasis are both long-term inflammatory conditions that share similar immune system pathways. Both diseases involve cytokines like tumor necrosis factor-alpha, interleukin (IL)-17, and IL-23. Currently, treatment choices for HS are limited, with only adalimumab and secukinumab approved for severe cases. Since HS and psoriasis have overlapping causes, drugs that target IL-17 and IL-23 could be really useful in managing HS.

Researchers from different medical centers looked back at patient records to study the effectiveness of these anti-IL-17/23 drugs. They focused on patients with both moderate to severe HS and psoriasis. The study aimed to see if these drugs could improve HS symptoms in such cases. The results showed that these drugs had a positive impact on HS, suggesting they could be a valuable addition to current treatment options. It's important to note that while these drugs show promise, more research is needed to fully understand their long-term effects and potential side effects. Also, not all patients responded equally well to the treatment, highlighting the need for personalized approaches.

Actions